Take part in a one-to-one session and help us improve the FRA website. It will take about 30 minutes of your time.
YES, I AM INTERESTED NO, I AM NOT INTERESTED
Article 48 - Presumption of innocence and right of defence
Key facts of the case:
APPLICATION for annulment in part of Commission Decision C(2013) 3803 final of 19 June 2013 relating to a proceeding under Article 101 [TFEU] and Article 53 of the EEA Agreement (Case AT.39226 — Lundbeck) and for reduction of the amount of the fine imposed on the applicants by that decision.
Competition — Agreements, decisions and concerted practices — Market for antidepressant medicinal products containing the active pharmaceutical ingredient citalopram — Concept of restriction of competition ‘by object’ — Potential competition — Generic medicinal products — Barriers to market entry resulting from the existence of patents — Agreement concluded between a patent holder and a generic undertaking — Duration of the Commission’s investigation - Rights of the defence — Fines — Legal certainty — Principle that penalties must have a proper legal basis)
Results (sanctions) and key consequences of the case:
...the General Court (Ninth Chamber) hereby: 1. Dismisses the action; 2. Orders Xellia Pharmaceuticals ApS and Alpharma LLC to pay the costs.
68. It is necessary to take into account the principle of the presumption of innocence resulting in particular from Article 48 of the Charter of Fundamental Rights of the European Union. Given the nature of the infringements in question and the nature and degree of severity of the penalties which may ensue, the presumption of innocence applies, inter alia, to the procedures relating to infringements of the competition rules applicable to undertakings that may result in the imposition of fines or periodic penalty payments (see, to that effect, judgment in CISAC v Commission, cited in paragraph 66 above, EU:T:2013:188, paragraph 93 and the case-law cited).